Suchergebnisse - "McQueen, R Brett"

PubPharm (16)

1

Incorporating Dynamic Pricing in Cost-Effectiveness Analysis: Are Known Unknowns Valuable?

enthalten in: PharmacoEconomics | 2023

von McQueen, R. | Anderson, K. | Levy, J. | +1

2

Potential Cardiovascular Events Avoided with Bempedoic Acid Plus Ezetimibe Fixed-Dose Combination Compared with Ezetimibe Alone in Patients with Atherosclerotic Cardiovascular Disease Taking Maximally Tolerated Statins

enthalten in: American journal of cardiovascular drugs | 2022

von McQueen, R. | Baum, S. | Louie, M. | +6

3

Correction to: Contextual Considerations and Recommendations for Estimating the Value of Alzheimer’s Disease Therapies

enthalten in: PharmacoEconomics | 2022

von Mattingly, T. | McQueen, R. | Lin, P.

4

Contextual Considerations and Recommendations for Estimating the Value of Alzheimer’s Disease Therapies

enthalten in: PharmacoEconomics | 2021

von Mattingly, T. | McQueen, R. | Lin, P.

5

Toward Modified Impact Inventory Tables to Facilitate Patient-Centered Value Assessment

enthalten in: PharmacoEconomics | 2021

von McQueen, R. | Slejko, J.

6

Economic Impact of Coverage Expansion for Non-invasive Prenatal Testing Through a Performance-Based Risk-Sharing Agreement

enthalten in: PharmacoEconomics - open | 2021

von Quinlan, T. | Schroeder, B. | Kwon, S. | +5

7

A Critical Appraisal and Recommendations for Cost-Effectiveness Studies of Poly(ADP-Ribose) Polymerase Inhibitors in Advanced Ovarian Cancer

enthalten in: PharmacoEconomics | 2020

von Gao, W. | Muston, D. | Monberg, M. | +8

8

What Value Does the NCCN Affordability Rating Really Provide to Patients, Providers, and Society?

enthalten in: PharmacoEconomics | 2020

von McQueen, R.

9

Achieving Appropriate Model Transparency: Challenges and Potential Solutions for Making Value-Based Decisions in the United States

enthalten in: PharmacoEconomics | 2019

von Carlson, J. | Walton, S. | Basu, A. | +8

10

Comment on “Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States”

enthalten in: PharmacoEconomics | 2019

von McQueen, R. | Whittington, M. | Chapman, R. | +2